Characterizing expanded access and compassionate use programs for experimental drugs

Jennifer E. Miller, Joseph S. Ross, Kenneth I. Moch and Arthur L. Caplan BMC Research Notes 2017 10:350
We sought to determine the characteristics of “expanded access” and “compassionate use” programs registered in and to determine the percentage of drugs provided through these programs that ultimately received FDA marketing approval.